Search

This paper reviews the ecosystem of GATE, an open-source Monte Carlo toolkit for medical physics. Based on the shoulders of Geant4, the principal modules (geometry, physics, scorers) are described with brief descriptions of some key concepts (Volume, Actors, Digitizer). The main source code repositories are detailed together with the automated compilation and tests processes (Continuous Integration). We then described how the OpenGATE collaboration managed the collaborative development of about one hundred developers during almost 20 years. The impact of GATE on medical physics and cancer research is then summarized, and examples of a few key applications are given. Finally, future development perspectives are indicated.

The GATE toolkit (GEANT4 Application for Tomographic Emission) is a GEANT4-based (GEometry ANd Tracking) platform for Monte Carlo simulations in medical physics. GATE applications can be divided into two main axes: radiation-based medical imaging and radiotherapy/dosimetry. The accurate modeling of the first one is crucial for system design and optimization as well as for development and refinement of image analysis algorithms. The importance of the precise simulation of the second is essential for characterisation of external beam radiotherapy (proton therapy and carbon ion therapy) and absorbed dose assessment. Within this paper, we discuss the main features of GATE and give a general view on applications, followed by insights into future development perspectives.

Objective. In carbon ion therapy, the visualization of the range of incident particles in a patient body is important for treatment verification. In-beam positron emission tomography (PET) imaging is one of the methods to verify the treatment in ion therapy due to the high quality of PET images. We have shown the feasibility of in-beam PET imaging of radioactive 15O and 11C ion beams for range verification using our OpenPET system. Recently, we developed a whole gamma imager (WGI) that can simultaneously work as PET, single gamma ray and triple gamma ray imaging. The WGI has high potential to detect the location of 10C, which emits positrons with a simultaneous gamma ray of 718 keV, within the patient’s body during ion therapy. Approach. In this work, we focus on investigating the performance of WGI for 10C imaging and its feasibility for range verification in carbon ion therapy. First, the performance of the WGI was studied to image a 10C point source using the Geant4 toolkit. Then, the feasibility of WGI was investigated for an irradiated polymethyl methacrylate (PMMA) phantom with a 10C ion beam at the carbon therapy facility of the Heavy Ion Medical Accelerator in Chiba. Main results. The average spatial resolution and sensitivity for the simulated 10C point source at the centre of the field of view were 5.5 mm FWHM and 0.010%, respectively. The depth dose of the 10C ion beam was measured, and the triple gamma image of 10C nuclides for an irradiated PMMA phantom was obtained by applying a simple back projection to the detected triple gammas. Significance. The shift between Bragg peak position and position of the peak of the triple gamma image in an irradiated PMMA phantom was 2.8 ± 0.8 mm, which demonstrates the capability of triple gamma imaging using WGI for range verification of 10C ion beams. [ABSTRACT FROM AUTHOR]

In heavy-ion therapy, the stopping position of primary ions in tumours needs to be monitored for effective treatment and to prevent overdose exposure to normal tissues. Positron-emitting ion beams, such as 11C and 15O, have been suggested for range verification in heavy-ion therapy using in-beam positron emission tomography (PET) imaging, which offers the capability of visualizing the ion stopping position with a high signal-to-noise ratio. We have previously demonstrated the feasibility of in-beam PET imaging for the range verification of 11C and 15O ion beams and observed a slight shift between the beam stopping position and the dose peak position in simulations, depending on the initial beam energy spread. In this study, we focused on the experimental confirmation of the shift between the Bragg peak position and the position of the maximum detected positron-emitting fragments via a PET system for positron-emitting ion beams of 11C (210 MeV u−1) and 15O (312 MeV u−1) with momentum acceptances of 5% and 0.5%. For this purpose, we measured the depth doses and performed in-beam PET imaging using a polymethyl methacrylate (PMMA) phantom for both beams with different momentum acceptances. The shifts between the Bragg peak position and the PET peak position in an irradiated PMMA phantom for the 15O ion beams were 1.8 mm and 0.3 mm for momentum acceptances of 5% and 0.5%, respectively. The shifts between the positions of two peaks for the 11C ion beam were 2.1 mm and 0.1 mm for momentum acceptances of 5% and 0.5%, respectively. We observed larger shifts between the Bragg peak and the PET peak positions for a momentum acceptance of 5% for both beams, which is consistent with the simulation results reported in our previous study. The biological doses were also estimated from the calculated relative biological effectiveness (RBE) values using a modified microdosimetric kinetic model (mMKM) and Monte Carlo simulation. Beams with a momentum acceptance of 5% should be used with caution for therapeutic applications to avoid extra dose to normal tissues beyond the tumour when the dose distal fall-off is located beyond the treatment volume. [ABSTRACT FROM AUTHOR]

PET is a powerful molecular imaging technique that can provide functional information on living objects. However, the spatial resolution of PET imaging has been limited to around 1 mm, which makes it difficult to visualize mouse brain function in detail. Here, we report an ultrahigh-resolution small-animal PET scanner we developed that can provide a resolution approaching 0.6 mm to visualize mouse brain function with unprecedented detail. Methods: The ultrahigh-resolution small-animal PET scanner has an inner diameter of 52.5 mm and axial coverage of 51.5 mm. The scanner consists of 4 rings, each of which has 16 depth-of-interaction detectors. Each depth-of-interaction detector consists of a 3-layer staggered lutetium yttrium orthosilicate crystal array with a pitch of 1 mm and a 4 × 4 silicon photomultiplier array. The physical performance was evaluated in accordance with the National Electrical Manufacturers Association NU4 protocol. Spatial resolution was evaluated with phantoms of various resolutions. In vivo glucose metabolism imaging of the mouse brain was performed. Results: Peak absolute sensitivity was 2.84% with an energy window of 400-600 keV. The 0.55-mm rod structure of a resolution phantom was resolved using an iterative algorithm. In vivo mouse brain imaging with 18 F-FDG clearly identified the cortex, thalamus, and hypothalamus, which were barely distinguishable in a commercial preclinical PET scanner that we used for comparison. Conclusion: The ultrahigh-resolution small-animal PET scanner is a promising molecular imaging tool for neuroscience research using rodent models., (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)

The spatial resolution of small animal positron emission tomography (PET) scanners can be improved by the use of crystals with fine pitch and rejection of inter-crystal scattering (ICS) events, which leads to a better quantification of radiopharmaceuticals. On the other hand, depth-of-interaction (DOI) information is essential to preserve the spatial resolution at the PET field-of-view (FOV) periphery while keeping the sensitivity. In this study we proposed a novel staggered 3-layer DOI detector using BaSO 4 reflector material for an enhanced crystal identification performance as well as ICS event rejection capability over those of ESR reflector based DOI detectors. The proposed staggered 3-layer DOI detector had 3-layer staggered LYSO crystal arrays (crystal pitch = 1 mm), an acrylic light guide, and a 4 × 4 SiPM array. The 16 SiPM anode signals were read out by using a resistive network to encode the crystal position and energy information while the timing signal was extracted from the common cathode. The crystal map quality was substantially enhanced by using the BaSO 4 reflector material as compared to that of the ESR reflector due to the low optical crosstalk between the LYSO crystals. The ICS events can be rejected with BaSO 4 by using simple pulse height discrimination thanks to the light collection efficiency difference that depends on the crystal layers. As a result, the total number of events was decreased around 26% with BaSO 4 as compared to that of ESR. The overall energy resolution and coincidence timing resolution with BaSO 4 were 19.7 ± 5.6% and 591 ± 160 ps, respectively which were significantly worse than 10.9 ± 2.2% and 308 ± 23 ps values of ESR because of the relatively low light collection efficiency with BaSO 4 (1057 ± 308 ADC) compared to that of ESR (1808 ± 118 ADC). In conclusion, we found the proposed staggered 3-layer DOI detector using the BaSO 4 reflector material with ICS event rejection capability can be a cost-effective solution for realizing high resolution and highly sensitive small animal PET scanners while minimizing the complexity of the SiPM readout circuit., (© 2021 IOP Publishing Ltd.)

In heavy-ion therapy, the stopping position of primary ions in tumours needs to be monitored for effective treatment and to prevent overdose exposure to normal tissues. Positron-emitting ion beams, such as 11 C and 15 O, have been suggested for range verification in heavy-ion therapy using in-beam positron emission tomography (PET) imaging, which offers the capability of visualizing the ion stopping position with a high signal-to-noise ratio. We have previously demonstrated the feasibility of in-beam PET imaging for the range verification of 11 C and 15 O ion beams and observed a slight shift between the beam stopping position and the dose peak position in simulations, depending on the initial beam energy spread. In this study, we focused on the experimental confirmation of the shift between the Bragg peak position and the position of the maximum detected positron-emitting fragments via a PET system for positron-emitting ion beams of 11 C (210 MeV u -1 ) and 15 O (312 MeV u -1 ) with momentum acceptances of 5% and 0.5%. For this purpose, we measured the depth doses and performed in-beam PET imaging using a polymethyl methacrylate (PMMA) phantom for both beams with different momentum acceptances. The shifts between the Bragg peak position and the PET peak position in an irradiated PMMA phantom for the 15 O ion beams were 1.8 mm and 0.3 mm for momentum acceptances of 5% and 0.5%, respectively. The shifts between the positions of two peaks for the 11 C ion beam were 2.1 mm and 0.1 mm for momentum acceptances of 5% and 0.5%, respectively. We observed larger shifts between the Bragg peak and the PET peak positions for a momentum acceptance of 5% for both beams, which is consistent with the simulation results reported in our previous study. The biological doses were also estimated from the calculated relative biological effectiveness (RBE) values using a modified microdosimetric kinetic model (mMKM) and Monte Carlo simulation. Beams with a momentum acceptance of 5% should be used with caution for therapeutic applications to avoid extra dose to normal tissues beyond the tumour when the dose distal fall-off is located beyond the treatment volume.